Trials / Completed
CompletedNCT00986414
Evaluation of the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
13-week, Double-blind, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 260 (estimated)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 30 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This phase IIb study is designed to determine the safe and efficacious dose or dose range of AFQ056 for the treatment of patients with moderate to severe Parkinson's disease with L-Dopa induced dyskinesias.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AFQ056 | |
| DRUG | AFQ056 | |
| DRUG | AFQ056 | |
| DRUG | AFQ056 | |
| DRUG | AFQ056 | |
| DRUG | Placebo |
Timeline
- Start date
- 2009-09-01
- Primary completion
- 2010-12-01
- First posted
- 2009-09-30
- Last updated
- 2017-02-23
Locations
47 sites across 8 countries: Australia, Canada, Finland, France, Germany, Italy, Japan, Spain
Source: ClinicalTrials.gov record NCT00986414. Inclusion in this directory is not an endorsement.